HepatiCult™类器官培养基（人源）

用于人肝脏类器官生成、生长和分化的培养基试剂盒

率先评论此产品

产品号 #（选择产品）

产品号 #100-0386_C

用于人肝脏类器官生成、生长和分化的培养基试剂盒

产品优势

完整。提供完整的培养体系来建立、维持和分化人肝脏类器官。
高效。不同供体来源的肝组织均能实现高效的类器官的生成。
功能性。生成具有CYP3A4活性的成熟肝类器官。
灵活。允许不同的培养形式以灵活实验。

产品组分包括

HepatiCult™ 类器官基础培养基（人源），3 x 95 mL
类器官补充剂，50 mL
HepatiCult™ 类器官生长补充剂（人源），2 x 5 mL
HepatiCult™ 类器官分化补充剂（人源），5 mL

跳到结尾的图片库

跳转到图像库的开头

概述

稳定生成、扩增并分化具有生理相关性的人源肝脏类器官。与传统使用的模型系统（如细胞系和动物模型）相比，人源肝脏类器官为研究肝脏发育、再生、代谢及疾病提供了更具相关性的模型系统。

HepatiCult™ 类器官培养试剂盒（人源）包含从新鲜或冷冻保存的人源肝脏组织中培养类器官所需的所有组分：

• HepatiCult™ 类器官起始培养基（人源）——高效生成不同供体系来源的肝脏类器官
• HepatiCult™ 类器官生长培养基（人源）——用于扩增并维持肝脏类器官，供后续实验或生物样本库存储
• HepatiCult™ 类器官分化培养基（人源）——生成具有肝脏功能（包括CYP3A4活性）的成熟类器官。这些类器官可适配多种培养方案，包括二维单层培养、悬浮培养及高通量检测。

有关HepatiCult™类器官培养方案的更多信息，请参阅技术手册与教学资料。

如果您打算将此产品用于商业目的，请通过www.huborganoids.nl联系HUB以获得商业使用许可或有关HUB许可的说明。

Data Figures

Figure 1. HepatiCult™ Organoid Kit (Human) Enables Liver Organoid Initiation, Expansion, and Differentiation

Human liver organoids can be grown from normal human liver tissue-derived hepatic ducts using the HepatiCult™ Organoid Kit (Human). (A) Cultures are established in HepatiCult™ Organoid Initiation Medium (OIM; Human) or HepatiCult™ Organoid Growth Medium (OGM; Human) (see Table 1 below) and subsequently passaged in HepatiCult™ OGM for expansion. (B) After passaging 2-3 times in HepatiCult™ OGM, cultures can be switched to HepatiCult™ Organoid Differentiation Medium (ODM; Human) to differentiate organoids towards more mature hepatic cell types. Refer to the Product Manual (Document #10000008301) for full culturing protocols.

Table 1. Product Recommendations for Liver Organoid Initiation, Expansion, and Differentiation

The recommended configuration of the HepatiCult™ Organoid Kit (Human) may differ based on starting material and experimental goals. When establishing liver organoid cultures from human liver tissue, HepatiCult™ Organoid Initiation Medium (OIM; Human) is recommended for efficient organoid initiation (see Figure 2 below). The expansion of already established organoids (fresh in culture or cryopreserved) is supported by HepatiCult™ Organoid Growth Medium (OGM; Human). These organoids should be maintained for 2-3 passages before further differentiation using HepatiCult™ Organoid Differentiation Medium (ODM). Refer to the Product Manual (Document #10000008301) for full culturing protocols.

Figure 2. HepatiCult™ Organoid Kit (Human) Provides Efficient Organoid Initiation From Human Liver Tissue

(A) Organoid cultures were initiated in HepatiCult™ OIM, and then (B) passaged into HepatiCult™ OGM. For serum-free culture conditions, organoid cultures were both, (C) initiated in and (D) passaged in HepatiCult™ OGM. Culture images shown are from (A, C) day 15 following initiation, and (B, D) on day 8 of the first passage. (E) Quantification of organoid initiation efficiency shows a significantly higher organoid yield in HepatiCult™ OIM per gram of human liver tissue (mean ± SD; n=14).

Figure 3. HepatiCult™ Organoid Initiation Medium (Human) Supports Robust Organoid Establishment Across Multiple Liver Tissue Donor Samples

Organoids initiated from 4 donor tissue samples (A-D) exhibit morphological heterogeneity 15 days after initiation. All initiated cultures were subsequently expanded in HepatiCult™ OGM using a 1:1 passaging ratio (E-H), yielding healthy organoids at the end of the first passage.

Figure 4. Expansion of Organoid Cultures in HepatiCult™ Organoid Growth Medium

Hepatic organoids show efficient growth in HepatiCult™ OGM across multiple donors and passages with potential for indefinite culture. Organoids initiated using the serum-free workflow exhibited comparable growth rates when expanded in HepatiCult™ OGM (open markers).

Figure 5. Proliferating Hepatic Organoids Display Characteristics of Hepatic Progenitors

Human liver organoids grown in HepatiCult™ OGM display characteristics of proliferating hepatic progenitors observed through immunocytochemistry staining of (A) KI67, (B) HNF4A and (C) SOX9. Proliferating hepatic organoids also display characteristics of the hepatic epithelium including expression of (A) EPCAM. (B, C) Nuclei are counterstained with DAPI.

Figure 6. Proliferating Hepatic Organoids Maintain Genetic Expression Across Multiple Passages

Liver organoids maintained in HepatiCult™ OGM express stem cell markers (A) LGR5 and (B) AXIN2, ductal markers (C) SOX9 and (D) KRT19, as well as hepatic marker (E) HNF4a and (F) Albumin (ALB) across multiple passages, with minimal albumin expression observed during culture in HepatiCult™ OGM. Expression levels were measured by qPCR and normalized to TBP and UBC housekeeping genes to quantify relative expression levels. (mean ± SD; n = 2-5 organoid lines), * p < 0.05.

Figure 7. Organoid Differentiation Induces Changes in Organoid Morphology

Organoids exhibit a compact and dense morphology, often comprising thickened epithelia, upon switching cultures to HepatiCult™ Organoid Differentiation Medium (ODM). Shown are images of the same culture well over the course of the differentiation, including (A) day two of culture in HepatiCult™ OGM, (B) day five of culture, immediately after switching organoid cultures from HepatiCult™ OGM to HepatiCult™ ODM, (C) day seven of culture (two days after switching to ODM), (D) day ten of culture (five days after switching to ODM), and (E) day 15 of culture (ten days after switching to ODM). (F) Magnification of the rectangular section highlighted in (E).

Differentiation of Hepatic Organoids in HepatiCult™ ODM Induces Changes in Gene Expression Consistent with Hepatic Maturation As Analysed by RNA Sequencing

Figure 8. Differentiation of Hepatic Organoids in HepatiCult™ ODM Induces Changes in Gene Expression Consistent with Hepatic Maturation As Analysed by RNA Sequencing

Organoids expanded in HepatiCult™ OGM express markers associated with proliferative hepatic progenitor and ductal cells. Upon differentiation in HepatiCult™ ODM, organoids shift towards a more mature state, with increased expression levels of genes associated with key hepatic functions. This includes serum protein synthesis (ALB, SERPINA1), phase 1 and 2 drug metabolism (CYP2C9, CYP3A4, UGT1A1, GSTA1), glucose metabolism (SLC2A2, G6PC), bile acid synthesis (CYP27A1, BAAT), and urea synthesis (OTC). Genes associated with lipid and cholesterol metabolism are expressed at similar levels in both OGM and ODM organoids. Columns represent 3 biological replicates analyzed by bulk RNA-seq at passages 7 - 9 on day 5 in HepatiCult™ OGM and day 15 in HepatiCult™ ODM. The housekeeping gene, TBP, is included as a reference.

Figure 9. Differentiated Hepatic Organoids Demonstrate Functionality of Mature Hepatocytes

Upon differentiation in HepatiCult™ ODM, liver organoids were assayed for (A) albumin secretion, (B) CYP3A4 activity, (C) total bile acid production, and (D) urea production. Hepatic functionalities were compared to HepG2 cells and primary human hepatocytes (PHH), which were cultured in supplier-recommended media. Albumin secretion was detected using an ELISA kit (Abcam), total bile acid and urea production were analysed using colorimetric kits (Abcam), and CYP43A4 activity, referring to baseline activity without induction, was determined using the Luciferin-IPA kit (Promega). (mean ± SD; n = 3 organoid lines across 2 experiments, n = 2-3 technical replicates of HepG2 in 1 experiment, and n = 3 cryopreserved PHH donor samples in 1 experiment), * p < 0.05; ** p < 0.01.

Graphs demonstrating that CYP3A4 Activity Can Be Modulated in Differentiated Hepatic Organoids Upon Drug Treatment

Figure 10. CYP3A4 Activity Can Be Modulated in Differentiated Hepatic Organoids

Organoid cultures in HepatiCult™ ODM from three different donors were assessed for CYP3A4 (A) activity through LC-MS/MS and (B) gene expression through qPC R, demonstrating a time-dependent increase for both measurements. Gene expression levels were normalized to housekeeping genes, TBP and UBC, and ‘Day 0’ expression. To evaluate if CYP3A4 activity could be modulated, two differentiated hepatic organoid lines were treated with (C) calcitriol or (D) ketoconazole. CYP3A4 activity was assessed on day 15 of differentiation, 24 (open markers), or 48 hours post-treatment using the P450-Glo™ CYP3A4 assay (Luciferin-IPA) (Promega). Both differentiated hepatic organoid lines demonstrated a significant increase in CYP3A4 activity with increasing concentrations of calcitriol and a significant decrease in CYP3A4 activity with increasing concentrations of ketoconazole (n = 2 organoid lines, mean values from 2 experiments). Error bars = SD. One-way ANOVA with Dunnett's multiple comparisons test was used for statistical testing (**P ≤ 0.01, ****P ≤ 0.0001, ns = not significant).

IC50 Curves Demonstrating that High Drug Concentrations Disrupt Albumin Secretion in Differentiated Hepatic Organoids Consistent with Changes in Cell Viability

Figure 11. High Drug Concentrations Disrupt Albumin Secretion in Differentiated Hepatic Organoids

Organoids from two different donors were differentiated in HepatiCult™ ODM and treated with (A) troglitazone, (B) ketoconazole, (C) rifampicin, or (D) acetaminophen on day 7 of differentiation when the last media refresh was performed. Spent media was collected three days later on day 10, and accumulated albumin was measured using the MSD R-PLEX Human Albumin Assay. Organoids were also collected on day 10 and lysed for (E) viability assessments using the CellTiter-Glo® 3D Cell Viability Assay (Promega). Both differentiated hepatic organoid lines demonstrated a significant drop in secreted albumin upon treatment with high drug concentrations, corresponding with a decrease in cell viability (mean values from 2 experiments). Error bars = SD. One-way ANOVA with Tukey multiple comparisons test used for statistical testing (single asterisk or hash indicate P < 0.05, double asterisk or hash indicate P ≤ 0.01, triple asterisk or hash indicate P ≤ 0.001, quadruple asterisk indicate P ≤ 0.0001).

IC50 plots (drug dose-response viability curves) of primary hepatic organoids in comparison to HepG2 and PHH

Figure 12. Primary Hepatic Organoids Are Sensitive to Drug-Induced Hepatotoxicity in a Dose-Dependent Manner

Proliferating and differentiated hepatic organoids were treated with (A) troglitazone, (B) ketoconazole, (C) rifampicin, (D) acetaminophen, or 1% DMSO vehicle control for 3 days, with full-medium changes containing fresh compounds every 24 hours. Cell viability was assessed 24 hours after the last compound addition using the CellTiter-Glo® 3D Cell Viability Assay (Promega), and IC50 values were determined. These drug dose-response viability curves were compared to similarly treated HepG2 cells and primary human hepatocytes (PHH) cultured in 2D. Error bars = SD.

Figure 13. HepatiCult™ Organoid Kit Supports the Growth and Differentiation of Porcine Liver Organoids

Porcine liver organoids were established in HepatiCult™ Organoid Initiation Medium, and subsequently expanded for 4 passages in (A) HepatiCult™ Organoid Growth Medium (Human) and differentiated in (B, C) HepatiCult™ Organoid Differentiation Medium (Human). Organoids are stained with basolateral protein marker p120 (green), apical membrane and bile canaliculi marker F-Actin (purple), and nuclear dye Hoechst (blue). (D) Magnification of Panel C indicates bile canaliculi formation as seen through F-Actin staining. Scale bars = 50 μm. Data used with permission from Dr. Amy Engevik (Vanderbilt University Medical Center)

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type

Product Name

Catalog #

Lot #

Language

Document Type

Product Information Sheet

Product Name

HepatiCult™ Organoid Kit (Human)

Catalog #

100-0386

Lot #

All

Language

English

Document Type

Technical Manual

Product Name

HepatiCult™ Organoid Kit (Human)

Catalog #

100-0386

Lot #

All

Language

English

Document Type

Safety Data Sheet 1

Product Name

HepatiCult™ Organoid Kit (Human)

Catalog #

100-0386

Lot #

All

Language

English

Document Type

Safety Data Sheet 2

Product Name

HepatiCult™ Organoid Kit (Human)

Catalog #

100-0386

Lot #

All

Language

English

Document Type

Safety Data Sheet 3

Product Name

HepatiCult™ Organoid Kit (Human)

Catalog #

100-0386

Lot #

All

Language

English

Document Type

Safety Data Sheet 4

Product Name

HepatiCult™ Organoid Kit (Human)

Catalog #

100-0386

Lot #

All

Language

English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Research Area

Workflow Stages

Workflow Stages for Organoids

View All

更多信息